Skip to content Skip to footer

Supreme Court Justices Indicate They Probably Won’t Limit Access to Mifepristone

Two conservative justices seemed to give anti-abortion activists a blueprint for challenging the drug in the future.

A view of the U.S. Supreme Court on March 26, 2024, in Washington, D.C.

During oral arguments on Tuesday, the U.S. Supreme Court seemed unwilling to entertain notions from anti-abortion litigants regarding the safety and approval process of the abortion drug mifepristone, due to those individuals having no legal standing to make such challenges.

In a rare showing of bipartisanship across the bench, both liberal and conservative justices said that doctors and other challengers of the drug — many of whom have pushed unfounded claims of it being unsafe — simply couldn’t make the case that they had legal standing.

Those doctors, their lawyers claimed during arguments, were forced to treat patients who were purportedly adversely affected by mifepristone. But as the justices pointed out, those claims were dubious at best, due to health care providers being allowed to express conscientious objections to the medication and treating such individuals.

“Under federal law, no doctors can be forced against their consciences to perform or assist in an abortion, correct?” Justice Brett Kavanaugh pointed out.

Other justices of the Court, including Justice Elena Kagan, said that, outside of emergency situations — which the anti-abortion side didn’t seem to have any examples of — doctors and other medical personnel are allowed to voice their objections to treating patients.

The questions from various justices on the bench seemed to suggest that they would not render a verdict, likely set for June, that would regulate or even disallow the dispensing of mifepristone. The drug was approved in 2000, and was deregulated in 2016 and 2021, expanding how many weeks into pregnancy a person who wants an abortion can use it and allowing doctors to prescribe it and send it to patients through the mail via telemedicine.

Justices also bristled at the idea that the drug was unsafe. Directing her question toward lawyer Jessica Ellsworth, who represented the pharmaceutical company that produces mifepristone, Justice Ketanji Brown Jackson noted that it wasn’t the place of judges or justices to determine whether or not certain drugs were legal.

“Do you have concerns about judges, parsing medical and scientific studies?” Brown Jackson said to Ellsworth, who indicated that she did have such concerns and that there were other ways for people to object to the availability of purportedly unsafe drugs.

Claims by the anti-abortion side in the argument about the drug’s safety were indeed deeply flawed, and included citing anonymous blog posts on an anti-abortion website as “studies” and relying on “experts” with questionable claims regarding the abortion medication.

Only two justices seemed to indicate that they had qualms about the drug. Justice Samuel Alito focused on claims about the drug’s safety, in spite of those claims having problematic backgrounds, and both he and Justice Clarence Thomas asked questions about the Comstock Act, an 1873 statute that is no longer enforced but that once barred sending abortion medication and birth control through mail.

Still, observers of the case seemed to agree that the Supreme Court wouldn’t rule favorably for the anti-abortion side.

“I think the Supreme Court will side with the FDA and reject the challenge to mifepristone on standing grounds, probably 8–1, with Alito dissenting,” said Slate senior writer Mark Joseph Stern on X.

Stern noted, however, that discussion of the Comstock Act seemed to indicate that conservative justices were providing anti-abortion voices with a blueprint for how to challenge the drug.

Regardless of how the Court rules on this case, “it isn’t over,” Stern added.

Truthout reporter Mike Ludwig agreed, noting that, if the drug is successfully challenged in the future, access to birth control will likely be curtailed in addition to abortion.

A ruling from the Court limiting mifepristone “could invite further legal challenges to other medications that are used by millions of people but remain controversial on the right, including Plan B emergency contraception, birth control pills, vaccines and gender-affirming hormone therapy,” Ludwig said in his reporting on Tuesday.

We’re not backing down in the face of Trump’s threats.

As Donald Trump is inaugurated a second time, independent media organizations are faced with urgent mandates: Tell the truth more loudly than ever before. Do that work even as our standard modes of distribution (such as social media platforms) are being manipulated and curtailed by forces of fascist repression and ruthless capitalism. Do that work even as journalism and journalists face targeted attacks, including from the government itself. And do that work in community, never forgetting that we’re not shouting into a faceless void – we’re reaching out to real people amid a life-threatening political climate.

Our task is formidable, and it requires us to ground ourselves in our principles, remind ourselves of our utility, dig in and commit.

As a dizzying number of corporate news organizations – either through need or greed – rush to implement new ways to further monetize their content, and others acquiesce to Trump’s wishes, now is a time for movement media-makers to double down on community-first models.

At Truthout, we are reaffirming our commitments on this front: We won’t run ads or have a paywall because we believe that everyone should have access to information, and that access should exist without barriers and free of distractions from craven corporate interests. We recognize the implications for democracy when information-seekers click a link only to find the article trapped behind a paywall or buried on a page with dozens of invasive ads. The laws of capitalism dictate an unending increase in monetization, and much of the media simply follows those laws. Truthout and many of our peers are dedicating ourselves to following other paths – a commitment which feels vital in a moment when corporations are evermore overtly embedded in government.

Over 80 percent of Truthout‘s funding comes from small individual donations from our community of readers, and the remaining 20 percent comes from a handful of social justice-oriented foundations. Over a third of our total budget is supported by recurring monthly donors, many of whom give because they want to help us keep Truthout barrier-free for everyone.

You can help by giving today. Whether you can make a small monthly donation or a larger gift, Truthout only works with your support.